Mar 31, 2026 7:00am EDT Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
Mar 26, 2026 7:00am EDT Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
Mar 23, 2026 4:32pm EDT Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Mar 17, 2026 4:35pm EDT Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
Mar 12, 2026 5:30pm EDT Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Mar 10, 2026 8:00am EDT Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYA™ at the 8th International Congress on Controversies in Fibromyalgia
Mar 9, 2026 4:30pm EDT Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
Mar 5, 2026 4:15pm EST Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Mar 3, 2026 4:30pm EST Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
